Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
Titel:
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
Auteur:
Granholm, Anders Munch, Marie Warrer Myatra, Sheila Nainan Vijayaraghavan, Bharath Kumar Tirupakuzhi Cronhjort, Maria Wahlin, Rebecka Rubenson Jakob, Stephan M. Cioccari, Luca Kjær, Maj-Brit Nørregaard Vesterlund, Gitte Kingo Meyhoff, Tine Sylvest Helleberg, Marie Møller, Morten Hylander Benfield, Thomas Venkatesh, Balasubramanian Hammond, Naomi E. Micallef, Sharon Bassi, Abhinav John, Oommen Jha, Vivekanand Kristiansen, Klaus Tjelle Ulrik, Charlotte Suppli Jørgensen, Vibeke Lind Smitt, Margit Bestle, Morten H. Andreasen, Anne Sofie Poulsen, Lone Musaeus Rasmussen, Bodil Steen Brøchner, Anne Craveiro Strøm, Thomas Møller, Anders Khan, Mohd Saif Padmanaban, Ajay Divatia, Jigeeshu Vasishtha Saseedharan, Sanjith Borawake, Kapil Kapadia, Farhad Dixit, Subhal Chawla, Rajesh Shukla, Urvi Amin, Pravin Chew, Michelle S. Wamberg, Christian Aage Gluud, Christian Lange, Theis Perner, Anders